Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 14

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 14
---
 2.7(2) 
     - 
  
    Exercisable, September 30, 2025 
     2,814,057  
    $4.97  
     2.7(2) 
     - 

    (1)
    The
    warrants herein consist of various contractual terms. The warrants herein consist of 2,429,025 warrants issued to Bay Shore Trust
    that have a remaining contractual term of 4.5 years as of December 31, 2023, and 335,032 warrants issued to investors associated
    with the 2023 Private Placement that currently have an indeterminable contractual term.

    (2)
    The
    warrants herein consist of various contractual terms. The warrants herein consist of 2,429,025 warrants issued to Bay Shore Trust
    that have a remaining contractual term of 2.7 years as of September 30, 2025, 335,032 warrants issued to investors associated with
    the 2023 Private Placement that currently have an indeterminable contractual term, and 50,000 warrants issued to underwriters as
    part of the IPO with a remaining contractual life of 2.65 years. In connection with the IPO in February 2024, the Company issued
    50,000 warrants to purchase common stock to the IPO underwriter (or its designees) at an exercise price of $7.00. These warrants
    are exercisable immediately and will expire in the four-and-a-half-year period commencing six months after the February 2024 IPO.
    The warrants will be exercisable at any time and from time to time, in whole or in part. The warrants provide for registration rights
    (including a one-time demand registration right and piggyback registration rights that expire 5 years from the commencement of sales
    of the offering) and customary anti-dilution provisions as permitted under FINRA Rule 5110(g)(8).
  
 Private
placement Warrants

During
the year ended December 31, 2023, the Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase
up to 268,025 shares of common stock at an exercise price of $15.42 per share. The Company also issued to the placement agent a Common
Stock warrant the right to purchase up to 67,007 shares of common stock at an exercise price of $3.73